Cargando…
Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia
BACKGROUND: Promising clinical and humanistic outcomes are associated with the use of new oral agents in the treatment of relapsing-remitting multiple sclerosis (RRMS). This is the first cost-effectiveness study comparing these medications in Saudi Arabia. OBJECTIVES: We aimed to compare the cost-ef...
Autores principales: | Alsaqa’aby, Mai F., Vaidya, Varun, Khreis, Noura, Al Khairallah, Thamer, Al-jedai, Ahmed H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
King Faisal Specialist Hospital and Research Centre
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074120/ https://www.ncbi.nlm.nih.gov/pubmed/29229891 http://dx.doi.org/10.5144/0256-4947.2017.433 |
Ejemplares similares
-
Impact of depression and fatigue on relapsing remitting multiple sclerosis in Kingdom of Saudi Arabia
por: Alshamrani, Foziah J., et al.
Publicado: (2020) -
Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab
por: Craner, Matthew, et al.
Publicado: (2022) -
Effect of Seasonal Variation on Relapse Rate in Patients With Relapsing-Remitting Multiple Sclerosis in Saudi Arabia
por: Makkawi, Seraj, et al.
Publicado: (2022) -
Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023) -
Cancer Management in Saudi Arabia: Recommendations by the Saudi Oncology HeAlth Economics ExpeRt GrouP (SHARP)
por: Alkhudair, Nora, et al.
Publicado: (2021)